We are redefining synthetic lethality, turning cancer patients into cancer survivors

Innovator in synthetic lethality

At Tesselate Bio, we are exploring new synthetic lethal interactions beyond Homologous Recombination Deficiency (HRD), uncovering novel biology and mechanisms to create a pipeline of first-in-class precision medicines that address significant unmet needs for patients.

Learn more

Precision oncology strategy

Committed to precision oncology approaches, we incorporate biomarker discovery and companion diagnostics (CDx) early in our discovery programs.

Learn more

World class team

Our leadership team of experienced drug hunters is leveraging their experiences to shape our pioneering science and pipeline of first-in-class precision oncology medicines.

Learn more

Latest News

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer 4 November 2024
Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers 30 September 2024

View all news